Product Description: Atacicept (TACI-Ig) is a is a recombinant fusion protein containing the extracellular, ligand-binding portion of the TACI receptor and the Fc portion of human IgG. Atacicept inhibits B cell stimulation by binding to B lymphocyte stimulator and a proliferation-inducing ligand. Atacicept can be used in research of B-cell autoimmune disease[1][2].
Applications: COVID-19-immunoregulation
Formula: N/A
References: [1]Gross JA, et, al. TACI-Ig neutralizes molecules critical for B cell development and autoimmune disease. impaired B cell maturation in mice lacking BLyS. Immunity. 2001 Aug;15(2):289-302. /[2]Gross JA, et, al. TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature. 2000 Apr 27;404(6781):995-9.
CAS Number: 845264-92-8
Molecular Weight: N/A
Compound Purity: 99.50
Research Area: Inflammation/Immunology
Solubility: 10 mM in DMSO
Target: Others
English
Deutsch
